Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Issue 10 (2nd October 2016)

• Record Type: Journal Article
• Authors: Passaro, Antonio; Pochesci, Alessia; Spitaleri, Gianluca; Catania, Chiara; Noberasco, Cristina; Del Signore, Ester; de Marinis, Filippo
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 10(2016)
• Page Start: 1283
• Page End: 1288
• Publication Date: 2016-10-02
• Subjects: NSCLC -- EGFR -- afatinib -- lung cancer -- TKI -- tyrosine kinase inhibitor -- LUX-Lung 7 -- dose reduction -- uncommon mutation; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2016.1233059
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction : Epidermal growth factor receptor (EGFR) mutations are detected in about 10–15% of Caucasian and 30–40% of Asian patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In patients harbouring EGFR mutations, the treatment with different available EGFR tyrosine kinase inhibitors (TKIs) showed to be more effective and safe than platinum-based chemotherapy regimens. Areas covered : The current evidences about the role of afatinib for patients with EGFR-positive NSCLC are reviewed and discussed. We report a review based on a MEDLINE/PubMed, searched for randomized phase II or III trials evaluating afatinib in EGFR-positive NSCLC. Expert commentary : Afatinib is the third EGFR TKI approved for the treatment of NSCLC harbouring EGFR mutations, showing high efficacy in this setting of patients.